Nicole Chemaly

Nicole Chemaly

Auto-generated profile, based on publicly available information

Nicole Chemaly

Department of Pediatric Neurology, Reference Center for Rare Epilepsies Hôpital Necker‐Enfants Malades, member of ERN EpiCARE Paris France

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2023 in Developmental Medicine & Child Neurology
Verified
Journal Article
Open access
CCCatherine Chiron
Catherine Chiron
NCNicole Chemaly
Nicole Chemaly
LCLaurent Chancharme
Laurent Chancharme
RNRima Nabbout
Rima Nabbout
Aim: To evaluate the safety and efficacy of stiripentol initiated before 2 years of age in patients with Dravet syndrome.Method: This was a 30‐year, real‐world retrospective study. We extracted the data of the 131 patients (59 females, 72 males) who initiated stiripentol before 2 years of age between 1991 and 2021 from the four longitudinal databases of Dravet syndrome available in France.Results: Stiripentol was added to valproate and clobazam (93%) at 13 months and a median dose of 50 mg/kg/day. With short‐term therapy (<6 months on stiripentol, median 4 months, median age 16 months), the frequency of tonic–clonic seizures (TCS) lasting longer than 5 minutes decreased (p < 0.01) and status epilepticus (>30 minutes) disappeared in 55% of patients. With long‐term therapy (last visit on stiripentol <7 years of age, median stiripentol 28 months, median age 41 months), the frequency of long‐lasting TCS continued to decline (p = 0.03). Emergency hospitalizations dropped from 91% to 43% and 12% with short‐ and long‐term therapies respectively (p < 0.001). Three patients died, all from sudden unexpected death in epilepsy. Three patients discontinued stiripentol for adverse events; 55% reported at least one adverse event, mostly loss of appetite/weight (21%) and somnolence (11%). Stiripentol was used earlier, at lower doses, and was better tolerated by patients in the newest database than in the oldest (p < 0.01).Interpretation: Initiating stiripentol in infants with Dravet syndrome is safe and beneficial, significantly reducing long‐lasting seizures including status epilepticus, hospitalizations, and mortality in the critical first years of life.

20 December 2023 in Epilepsia
Verified
Journal Article
Open access
MKMathieu Kuchenbuch
Mathieu Kuchenbuch
TBTommaso Lo Barco
Tommaso Lo Barco
NCNicole Chemaly
Nicole Chemaly
CCCatherine Chiron
Catherine Chiron
RNRima Nabbout
Rima Nabbout
Objective: This study was undertaken to evaluate our treatment algorithm for infantile epileptic spasms syndrome (IESS) used between 2000 and 2018. We initiated vigabatrin (VGB), and steroids were added if the electroclinical response (spasms and electroencephalogram [EEG]) to VGB was not obtained or incomplete.Methods: Individuals with IESS treated with VGB were recruited from our hospital clinical data warehouse based on electronic health records (EHRs) generated since 2009 and containing relevant keywords. We confirmed the diagnosis of IESS. Clinical, EEG, imaging, and biological data were extracted from the EHRs. We analyzed factors associated with short‐term response, time to response, relapse, time to relapse of spasms, and the presence of spasms at last follow‐up.Results: We collected data from 198 individuals (female: 46.5%, IESS onset: 6 [4.5–10.3] months, follow‐up: 4.6 [2.5–7.6] years, median [Q1–Q3]) including 129 (65.2%) with identifiable etiology. VGB was started 17 (5–57.5) days after IESS diagnosis. A total of 113 individuals were responders (57.1% of the cohort), 64 with VGB alone and 38 with VGB further combined with steroids (56.6% and 33.6% of responders, respectively). Among responders, 33 (29%) experienced relapses of spasms, mostly those with later onset of spasms (p = .002) and those who received VGB for <24 months after spasms cessation compared to a longer duration on VGB (45% vs. 12.8%, p = .003). At follow‐up, 92 individuals were seizure‐free (46.5% of the whole cohort), including 26 free of therapy (13.1%). One hundred twelve individuals (56.6%) were still receiving VGB, with a duration of 3.2 (1.75–5.7) years.Significance: Our sequential protocol introducing VGB then adding steroids is an effective alternative to a combined VGB–steroids approach in IESS. It avoids steroid‐related adverse events, as well as those from VGB–steroid combination. According to our data, a period of 7 days seems sufficient to assess VGB response and enables the addition of steroids rapidly if needed. Continuing VGB for 2 years may balance the risk of relapse and treatment‐induced adverse events.

3 May 2016 in Neurology
Verified
Journal Article
Open access
PDF file
MHMarie Hully
Marie Hully
DGDavid Grevent
David Grevent
DBDelphine Breuillard
Delphine Breuillard
FBFrancis Brunelle
Francis Brunelle
NCNicole Chemaly
Nicole Chemaly
RNRima Nabbout
Rima Nabbout

22 September 2022 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
GPG. Pouliquen
G. Pouliquen
LFL. Fillon
L. Fillon
VDV. Dangouloff-Ros
V. Dangouloff-Ros
MKM. Kuchenbuch
M. Kuchenbuch
CBC. Bar
C. Bar
NBN. Boddaert
N. Boddaert
BACKGROUND AND PURPOSE: Sturge-Weber syndrome is a rare congenital neuro-oculo-cutaneous disorder. Although the principal mechanism of Sturge-Weber syndrome is characterized by a leptomeningeal vascular malformation, few data regarding perfusion abnormalities of the brain parenchyma are available. Therefore, the aim of this study was to assess the diagnostic performance of arterial spin-labeling perfusion imaging in the early stage of Sturge-Weber syndrome before 1 year of age until 3.5 years of age. We hypothesized that a leptomeningeal vascular malformation has very early hypoperfusion compared with controls with healthy brains. MATERIALS AND METHODS: We compared the CBF using arterial spin-labeling perfusion imaging performed at 3T MR imaging in the brain parenchymal regions juxtaposing the leptomeningeal vascular malformation in patients with Sturge-Weber syndrome (n = 16; 3.5 years of age or younger) with the corresponding areas in age-matched controls with healthy brains (n = 58). The analysis was performed following two complementary methods: a whole-brain voxel-based analysis and a visual ROI analysis focused on brain territory of the leptomeningeal vascular malformation. RESULTS: Whole-brain voxel-based comparison revealed a significant unilateral decrease in CBF localized in the affected cortices of patients with Sturge-Weber syndrome (P < .001). CBF values within the ROIs in patients with Sturge-Weber syndrome were lower than those in controls (in the whole cohort: median, 25 mL/100g/min, versus 44 mL/100g/min; P < .001). This finding was also observed in the group younger than 1 year of age, emphasizing the high sensitivity of arterial spin-labeling in this age window in which the diagnosis is difficult. CONCLUSIONS: Arterial spin-labeling perfusion imaging in the early stage of Sturge-Weber syndrome can help to diagnose the disease by depicting a cortical hypoperfusion juxtaposing the leptomeningeal vascular malformation.

18 September 2025 in European Journal of Neurology
Verified
Journal Article
Open access
NCNicole Chemaly
Nicole Chemaly
MKMathieu Kuchenbuch
Mathieu Kuchenbuch
ELEmma Losito
Emma Losito
AKAnna Kaminska
Anna Kaminska
DCDelphine Coste‐Zeitoun
Delphine Coste‐Zeitoun
RNRima Nabbout
Rima Nabbout
Background: Highly purified Cannabidiol (CBD, epidiolex) is approved for treating Lennox–Gastaut syndrome (LGS), Dravet syndrome (DS), and tuberous sclerosis (TSC), with off‐label use in drug‐resistant epilepsies. The aim of this study is to evaluate efficacy, safety, and long‐term retention of CBD in a large pediatric population.Methods: We prospectively included all consecutive patients initiating CBD for drug‐resistant epilepsy at our pediatric tertiary center from 2019 to 2021. Efficacy and safety were assessed via parental questionnaires on seizure and non‐seizure outcomes at 1, 2, and 6 months, comparing each item to prior clinic visits. Retention rate was evaluated at 18 months.Results: We included 103 patients (mean age 11.2 years), with 47% receiving CBD for label‐approved syndromes (23 DS, 15 LGS, 10 TSC) and 53% off‐label. At 1 month, 54% of caregivers reported reduced seizure frequency and duration, with a positive overall impression in 62%. By months 2–6, 48% maintained seizure improvement, alongside sustained gains in communication (60%), alertness (54%), and motor skills (44%). Retention rates were 97% at 1 month, 90% at 2 months, 82% at 6 months, 66% at 12 months, and 55% at 18 months. Off‐label use (p = 0.02), male gender (p = 0.049), and older age at initiation (p = 0.03) were associated with higher retention.Conclusions: CBD reduced seizures and improved non seizures' morbidities in drug‐resistant epilepsy. Strong 18‐month retention rate, including off‐label use, highlights efficacy and tolerability, underscoring the need for further real‐world data in various rare epilepsy syndromes beyond its market approval.

12 October 2026 in Epilepsia
Verified
Journal Article
Open access
TBTommaso Lo Barco
Tommaso Lo Barco
MDMaxime Douillet
Maxime Douillet
NCNicole Chemaly
Nicole Chemaly
ADAudrey Duval
Audrey Duval
GDGianluca D'ONofrio
Gianluca D'ONofrio
RNRima Nabbout
Rima Nabbout
Objective: Sleep disorders are frequent but undercharacterized comorbidities in developmental and epileptic encephalopathies (DEEs). We aimed to estimate the frequency, spectrum, and burden of sleep disturbances across genetic DEE subtypes using real‐world data extracted from electronic health records (EHRs) through natural language processing (NLP). Methods: We conducted a retrospective cohort study using Dr. Warehouse, an NLP‐enabled clinical data warehouse, at a tertiary pediatric center. Data were extracted from January to April 2025. Patients with a group of defined DEEs were identified from narrative clinical notes and matched 1:2 with pediatric neurology patients without history of epilepsy by age, follow‐up duration, and document volume. Predefined sleep‐related terms were extracted from free‐text reports. The proportion of patients with ≥1 documented mention during follow‐up was used to estimate occurrence, alongside multivariable logistic regression analyses and a cumulative sleep burden score. Results: The final cohort included 884 patients with DEE and 1280 matched controls. At least one sleep‐related disturbance was documented in 63.7% of DEE patients, significantly higher than in controls. The most frequent terms were “sleep disorder,” “nocturnal seizures,” and “night awakenings.” Marked heterogeneity emerged across DEE subtypes; SYNGAP1 ‐DEE showed the highest frequency of sleep disorders, Lennox–Gastaut syndrome was strongly associated with nocturnal seizures, and KCNT1 ‐ and PCDH19 ‐DEE were more frequently associated with sleep apnea. DEE patients also exhibited a significantly higher cumulative burden of sleep disturbances compared with controls, with Lennox–Gastaut syndrome showing the greatest burden. Significance: NLP‐based mining of unstructured EHR data enables large‐scale characterization of sleep disorders in DEEs, revealing DEE subtype‐specific sleep phenotypes. Routine and etiology‐informed assessment of sleep disturbances should be integrated into the clinical management of DEEs.